Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

$171.13 +1.73 (+1.02%)

As of 12:52 PM Eastern

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 11 Analyst Ratings

Sell
0

Hold
7

Buy
4

Based on 11 Wall Street analysts who have issued ratings for Becton, Dickinson and Company in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 7 have given a hold rating, and 4 have given a buy rating for BDX.

Consensus Price Target

$219.22
28.10% Upside

According to the 11 analysts' twelve-month price targets for Becton, Dickinson and Company, the average price target is $219.22. The highest price target for BDX is $290.00, while the lowest price target for BDX is $185.00. The average price target represents a forecasted upside of 28.10% from the current price of $171.13.

Get the Latest News and Ratings for BDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Becton, Dickinson and Company and its competitors.

BDX Analyst Ratings Over Time

Type	Current Forecast 6/3/24 to 6/3/25	1 Month Ago 5/4/24 to 5/4/25	3 Months Ago 3/5/24 to 3/5/25	1 Year Ago 6/4/23 to 6/3/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)
Hold	7 Hold rating(s)	6 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$219.22	$235.88	$278.29	$280.17
Forecasted Upside	28.10% Upside	39.89% Upside	24.14% Upside	17.27% Upside
Consensus Rating	Hold	Hold	Buy	Moderate Buy

BDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Becton, Dickinson and Company Stock vs. The Competition

Type	Becton, Dickinson and Company	Medical Companies	S&P 500
Consensus Rating Score	2.36	2.81	2.54
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	28.93% Upside	5,786.79% Upside	15.42% Upside
News Sentiment Rating	Positive News See Recent BDX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/3/2025	Barclays 3 of 5 stars	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$261.00 ➝ $241.00	+42.38%
5/22/2025	Citigroup 2 of 5 stars	Joanna Wiensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$217.00 ➝ $185.00	+6.78%
5/6/2025	Morgan Stanley 3 of 5 stars	Patrick Wood Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$280.00 ➝ $196.00	+18.22%
5/2/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$280.00 ➝ $224.00	+34.05%
5/2/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jason Bednar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$260.00 ➝ $185.00	+9.11%
5/2/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Roman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$192.00	+13.24%
5/2/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Bedford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/1/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
5/1/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$190.00	+8.61%
5/1/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Weinstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
Get the Latest News and Ratings for BDX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Becton, Dickinson and Company and its competitors with MarketBeat's FREE daily newsletter.
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$286.00 ➝ $290.00	+20.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:08 PM ET.

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, May 31, 2025. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to [email protected].

Becton, Dickinson and Company
Bull Case

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

The current stock price is around $172.53, which may present a buying opportunity for investors looking for value in the healthcare sector.
Becton, Dickinson and Company has a strong market capitalization of approximately $49.45 billion, indicating a solid position in the industry.
The company has a consistent dividend payout, currently at $4.16 annually, providing a yield of 2.41%, which can be attractive for income-focused investors.
Recent analyst ratings show a consensus price target of $221.44, suggesting potential upside for investors based on current valuations.
With a diverse range of medical supplies and devices, Becton, Dickinson and Company is well-positioned to benefit from ongoing demand in the healthcare sector.

Becton, Dickinson and Company
Bear Case

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

Recent downgrades from multiple analysts, including Citigroup and Bank of America, indicate a shift in market sentiment towards a more cautious outlook.
The company's payout ratio is currently at 79.39%, which may raise concerns about sustainability in dividend payments if earnings do not grow.
Insider selling activity has been noted, with executives reducing their ownership stakes, which could signal a lack of confidence in the company's near-term performance.
The stock has experienced a significant decline from its 52-week high of $251.99, which may indicate volatility and risk for potential investors.
With a beta of 0.31, the stock is less volatile than the market, but this could also mean limited growth potential compared to higher-risk investments.

BDX Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Becton, Dickinson and Company is $219.22, with a high forecast of $290.00 and a low forecast of $185.00.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BDX, but not buy additional shares or sell existing shares.
: According to analysts, Becton, Dickinson and Company's stock has a predicted upside of 28.10% based on their 12-month stock forecasts.
: Over the previous 90 days, Becton, Dickinson and Company's stock had 7 downgrades by analysts.
: Becton, Dickinson and Company has been rated by research analysts at Bank of America, Barclays, Citigroup, Morgan Stanley, Piper Sandler, Raymond James, Stifel Nicolaus, The Goldman Sachs Group, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Becton, Dickinson and Company less than other "medical" companies. The consensus rating for Becton, Dickinson and Company is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BDX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:BDX) was last updated on 6/3/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Becton, Dickinson and Company (BDX) Stock Forecast & Price Target